Tyra Biosciences, Inc. (TYRA)
| Market Cap | 1.50B +122.1% |
| Revenue (ttm) | n/a |
| Net Income | -148.57M |
| EPS | -2.40 |
| Shares Out | 59.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 567,917 |
| Open | 25.52 |
| Previous Close | 25.30 |
| Day's Range | 24.80 - 26.42 |
| 52-Week Range | 11.70 - 40.65 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | 50.82 (+102.23%) |
| Earnings Date | Aug 4, 2026 |
About TYRA
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for TYRA stock is "Strong Buy." The 12-month stock price target is $50.82, which is an increase of 102.23% from the latest price.
News
Tyra Biosciences price target lowered to $39 from $42 at BofA
BofA lowered the firm’s price target on Tyra Biosciences (TYRA) to $39 from $42 and keeps a Buy rating on the shares after updating the firm’s model to reflect the…
Tyra Biosciences price target lowered to $42 from $44 at Jefferies
Jefferies analyst Maury Raycroft lowered the firm’s price target on Tyra Biosciences (TYRA) to $42 from $44 and keeps a Buy rating on the shares. Tyra’s Q2 update “modestly pushes…
Tyra Biosciences delayed cancer data by one month, says JonesResearch
JonesResearch analyst Boris Peaker says that with its Q2 earnings report, Tyra Biosciences (TYRA) announced that the update from the Phase II SURF-302 clinical readout with dabogratinib in FGFR3-alter...
Tyra Biosciences falls 20% after pushing data readout to September from August
The stock in midday trading is down $6.39 to $26.15.
Tyra Biosciences reports Q2 EPS (69c), consensus (64c)
As of June 30 TYRA had cash, cash equivalents and marketable securities of $353.9M. The Company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute…
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose leve...
Tyra Biosciences Earnings release: Q2 2026
Tyra Biosciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Tyra Biosciences Quarterly report: Q2 2026
Tyra Biosciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
Tyra Biosciences assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Tyra Biosciences (TYRA) with an Outperform rating and $50 price target The firm views Tyra as a data-and-execution story entering a catalyst-rich stretch, anchored by t...
Tyra Biosciences initiated with a Buy at JonesResearch
JonesResearch initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $56 price target Tyra is a clinical-stage biotech company focused on developing therapeutics that target fibroblast gr...
Tyra Biosciences price target raised to $42 from $37 at BofA
BofA raised the firm’s price target on Tyra Biosciences (TYRA) to $42 from $37 and keeps a Buy rating on the shares. Ahead of the August readout for dabogratinib from…
Tyra Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Late-stage development is underway for dabogratinib in three FGFR3-driven indications, with key data readouts expected in August (NMIBC), Q4 (achondroplasia), and 2027 (UTUC). Oral administration offers a differentiated, less invasive approach with strong commercial potential and favorable safety expectations.
Tyra Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Phase II data for an oral therapy in NMIBC will be updated in August, targeting a 70%+ CR rate and robust safety profile, with rapid enrollment and strong patient preference for oral administration. Expansion into UTUC is underway, with initial data expected next year and significant market potential in both indications.
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Ty...
Tyra Biosciences initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Tyra Biosciences (TYRA) with a Peer Perform rating an no price target Tyra has dabogratinib in development for bladder cancer and achondroplasia, notes the analyst...
Tyra Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Dabogratinib is advancing in three late-stage indications—intermediate-risk NMIBC, UTUC, and achondroplasia—with pivotal data readouts expected in the coming year. The drug’s oral formulation and strong safety profile position it as a disruptive, best-in-class option in large, underserved markets.
Tyra Biosciences reports Q1 EPS (64c), consensus (59c)
As of March 31 TYRA had cash, cash equivalents and marketable securities of $383.5M. The Company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute…
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 20...
Tyra Biosciences Earnings release: Q1 2026
Tyra Biosciences released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Tyra Biosciences Quarterly report: Q1 2026
Tyra Biosciences has published its Q1 2026 quarterly earnings report on May 13, 2026.
Tyra Biosciences to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasda...
Tyra Biosciences Proxy statement: Proxy filing
Tyra Biosciences filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Tyra Biosciences Proxy statement: Proxy filing
Tyra Biosciences filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Tyra Biosciences initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $54 price target The firm says the company “has the right drug” to test three clinical…